4th Annual World Orphan Drug Congress USA, April 23rd -25th, 2014, Washington DC

Date: Dec-16-2013Orphan drug developers to discuss how to bring therapies to market faster

Though orphan drug designations have increased across established markets like US, Europe and Japan, high rates of clinical attrition as well as pricing & reimbursement issues remain problematic. Join over 600 industry and key stakeholders next April where these issues will be discussed and debated!

Join the 4th annual World Orphan Drug Congress USA, the largest global orphan drug conference! This will be held in Washington DC from April 23rd -25th, 2014.

Key speakers include Emil Kakkis, President and Founder of Ultragenyx, Congressman Leonard Lance, a Capitol Hill advocate of rare disease research, Christopher Austin, NIH's translation science division director, Roy Beveridge, Chief Medical Officer of private payer Humana, Bert Bruce, Pfizer's Rare Disease Unit Vice President for Commercial Operations and Betsy Garofalo, Novartis' recently appointed Head of Clinical Development Sciences.

This conference and expo provides a platform for key movers and shakers of the orphan drug industry to come together and discover partnerships and collaborations to expedite orphan drugs to patients globally.

Various facets to highlight key needs of the industry are as follows:

Hear inspiring keynote presentations from industry's key opinion leaders
Leverage from case studies across the entire process of orphan drug development at the Seminar Theater
Find bankable up and coming orphan drugs being developed by start-ups and scientist at the Pitch & Partner program
Evaluate, even purchase, the right product or service showcased at the Exhibit Area
Learn how to attract investment or how to best reach out to patient groups in-depth at the 3-hour pre-conference workshops
Meet over 50 patient groups at the Patient Zone in the Exhibit Area

Participants will learn:

How to successfully navigate new regulatory implementations like the breakthrough therapy designation
How to reassess the architecture and metrics of discovery, quantification and reimbursement of orphan drugs
How to ensure the market sustainability while maintaining orphan drugs' premium pricing
How to access emerging orphan drug markets like Brazil, China, Russia, Israel and MENA
How to launch and develop a successful patient registry

To register or learn more visit www.terrapinn.com/orphandrug  

Courtesy: Medical News Today Note: Any medical information available in this news section is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional.